NCT07646197
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Recruiting
NAAges 30–70InterventionalSupportive careHenry Ford Health SystemInvestigator-initiated
~125 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Peanut consumption
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hepatic Markers
Measured over Baseline to post-intervention (12 weeks)
Conditions
Where it's being run
1 sites across 1 statesMichigan1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
30-70 years
do not consume peanut/peanut butter/treenut/seeds \> /week
at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
Able to understand, speak, and read English
Mentally competent to consent
Exclusion
Food allergy to peanuts or peanut-containing products
With alcohol use disorder (AUDIT screening)
Leukemia
Lymphoma
Other types of cancer
Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)
What this trial measures
- Hepatic MarkersBaseline to post-intervention (12 weeks)
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention